Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christopher Brown

Physician Assistant Clinton, UT Physician Assistant

NPI 1710424619 CMS profile 10671630

1477 N 2000 W, Clinton, UT 84015

Open in the dashboard

General payments

$3,232

192 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Brown of Clinton, UT is reported in the CMS Open Payments database as having received $3,232 across 192 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $542 34
2024 General $654 32
2023 General $337 21
2022 General $846 50
2021 General $852 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Brown
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Christopher Brown were reported at $542. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Christopher Brown Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $852 $132 $37–$438 $132
2022 $846 $155 $48–$522 $149
2023 $337 $167 $52–$557 $160
2024 $654 $178 $55–$600 $164
2025 $542 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $567 36 payments
  2. AstraZeneca Pharmaceuticals LP $304 17 payments
  3. Lilly USA, LLC $240 17 payments
  4. Abbott Laboratories $173 8 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $145 7 payments
  6. Pfizer Inc. $144 7 payments
  7. Vanda Pharmaceuticals Inc. $142 3 payments
  8. GlaxoSmithKline, LLC. $140 10 payments
  9. ITI, Inc. $131 8 payments
  10. Dynavax Technologies Corporation $122 9 payments
  11. Other $1,123 70 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,219 191 payments
  2. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. VRAYLAR $299 16 payments
  2. BREZTRI $251 13 payments
  3. MOUNJARO $185 13 payments
  4. FARXIGA $158 6 payments
  5. UBRELVY $146 12 payments
  6. FANAPT $142 3 payments
  7. SYNJARDY $129 6 payments
  8. JARDIANCE $129 6 payments
  9. TRADJENTA $129 6 payments
  10. Heplisav-B $122 9 payments
  11. Other $2,558 157 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 49 drugs

Part D claims

1,274

Median for Physician Assistant: 241

Drug cost

$67,285

Median for Physician Assistant: $4,110

Branded share of claims

20.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Farxiga Dapagliflozin Propanediol Brand 29 $32,940
Ozempic Semaglutide Brand 24 $23,004
Celecoxib Generic 33 $751
Fluconazole Generic 66 $588
Losartan Potassium Generic 48 $586
Atorvastatin Calcium Generic 56 $552
Bupropion Xl Bupropion Hcl Brand 20 $494
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 47 $493
Omeprazole Generic 25 $490
Albuterol Sulfate Hfa Albuterol Sulfate Brand 30 $464

The 10 drugs with the highest cost, of 49 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 95 billing codes

Paid by Medicare

$35,043

Of which drugs: $2,475

Medicare patients

190

Average age 73

Services billed

5,586

110 women, 80 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 44%
Depression 36%
Chronic kidney disease 34%
Diabetes 32%
Ischemic heart disease 20%
Atrial fibrillation 15%
Cancer 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 11 11 $900
Injection, ketorolac tromethamine, per 15 mg J1885 Office 11 47 $20

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FANAPT
  • Vanda Pharmaceuticals Inc. $142
$142 — —
JORNAY PM
  • Ironshore Pharmaceuticals Inc. $66
$66 — —
Wegovy
  • Novo Nordisk Inc $62
$62 — —
MOUNJARO
  • Lilly USA, LLC $59
$59 — —
VRAYLAR
  • AbbVie, Inc. $49
$49 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

192 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record